The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Crigler-Najjar Syndrome Drug-Global Market Insights and Sales Trends 2025
Synopsis
The global Crigler-Najjar Syndrome Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Crigler-Najjar Syndrome Drug in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Crigler-Najjar Syndrome Drug market. ALXN-1540, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the AT-342 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Crigler-Najjar Syndrome Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Crigler-Najjar Syndrome Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Crigler-Najjar Syndrome Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Crigler-Najjar Syndrome Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Crigler-Najjar Syndrome Drug covered in this report include Audentes Therapeutics Inc, Genethon SA, International Stem Cell Corp and Promethera Biosciences SA, etc.
The global Crigler-Najjar Syndrome Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Audentes Therapeutics Inc
Genethon SA
International Stem Cell Corp
Promethera Biosciences SA
Global Crigler-Najjar Syndrome Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Crigler-Najjar Syndrome Drug market, Segment by Type:
ALXN-1540
AT-342
HepaStem
Others
Global Crigler-Najjar Syndrome Drug market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Crigler-Najjar Syndrome Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Crigler-Najjar Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Crigler-Najjar Syndrome Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Crigler-Najjar Syndrome Drug in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Crigler-Najjar Syndrome Drug market. ALXN-1540, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the AT-342 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Crigler-Najjar Syndrome Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Crigler-Najjar Syndrome Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Crigler-Najjar Syndrome Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Crigler-Najjar Syndrome Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Crigler-Najjar Syndrome Drug covered in this report include Audentes Therapeutics Inc, Genethon SA, International Stem Cell Corp and Promethera Biosciences SA, etc.
The global Crigler-Najjar Syndrome Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Audentes Therapeutics Inc
Genethon SA
International Stem Cell Corp
Promethera Biosciences SA
Global Crigler-Najjar Syndrome Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Crigler-Najjar Syndrome Drug market, Segment by Type:
ALXN-1540
AT-342
HepaStem
Others
Global Crigler-Najjar Syndrome Drug market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Crigler-Najjar Syndrome Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Crigler-Najjar Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Crigler-Najjar Syndrome Drug Market Overview
1.1 Crigler-Najjar Syndrome Drug Product Overview
1.2 Crigler-Najjar Syndrome Drug Market Segment by Type
1.2.1 ALXN-1540
1.2.2 AT-342
1.2.3 HepaStem
1.2.4 Others
1.3 Global Crigler-Najjar Syndrome Drug Market Size by Type
1.3.1 Global Crigler-Najjar Syndrome Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Crigler-Najjar Syndrome Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Crigler-Najjar Syndrome Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Crigler-Najjar Syndrome Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Crigler-Najjar Syndrome Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Crigler-Najjar Syndrome Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Crigler-Najjar Syndrome Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Crigler-Najjar Syndrome Drug Sales Breakdown by Type (2018-2023)
2 Global Crigler-Najjar Syndrome Drug Market Competition by Company
2.1 Global Top Players by Crigler-Najjar Syndrome Drug Sales (2018-2023)
2.2 Global Top Players by Crigler-Najjar Syndrome Drug Revenue (2018-2023)
2.3 Global Top Players by Crigler-Najjar Syndrome Drug Price (2018-2023)
2.4 Global Top Manufacturers Crigler-Najjar Syndrome Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Crigler-Najjar Syndrome Drug Market Competitive Situation and Trends
2.5.1 Crigler-Najjar Syndrome Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Crigler-Najjar Syndrome Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Crigler-Najjar Syndrome Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Crigler-Najjar Syndrome Drug Market
2.8 Key Manufacturers Crigler-Najjar Syndrome Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Crigler-Najjar Syndrome Drug Status and Outlook by Region
3.1 Global Crigler-Najjar Syndrome Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Crigler-Najjar Syndrome Drug Historic Market Size by Region
3.2.1 Global Crigler-Najjar Syndrome Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Crigler-Najjar Syndrome Drug Sales in Value by Region (2018-2023)
3.2.3 Global Crigler-Najjar Syndrome Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Crigler-Najjar Syndrome Drug Forecasted Market Size by Region
3.3.1 Global Crigler-Najjar Syndrome Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Crigler-Najjar Syndrome Drug Sales in Value by Region (2024-2029)
3.3.3 Global Crigler-Najjar Syndrome Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Crigler-Najjar Syndrome Drug by Application
4.1 Crigler-Najjar Syndrome Drug Market Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Crigler-Najjar Syndrome Drug Market Size by Application
4.2.1 Global Crigler-Najjar Syndrome Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Crigler-Najjar Syndrome Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Crigler-Najjar Syndrome Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Crigler-Najjar Syndrome Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Crigler-Najjar Syndrome Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Crigler-Najjar Syndrome Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Crigler-Najjar Syndrome Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Crigler-Najjar Syndrome Drug Sales Breakdown by Application (2018-2023)
5 North America Crigler-Najjar Syndrome Drug by Country
5.1 North America Crigler-Najjar Syndrome Drug Historic Market Size by Country
5.1.1 North America Crigler-Najjar Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Crigler-Najjar Syndrome Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Crigler-Najjar Syndrome Drug Sales in Value by Country (2018-2023)
5.2 North America Crigler-Najjar Syndrome Drug Forecasted Market Size by Country
5.2.1 North America Crigler-Najjar Syndrome Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Crigler-Najjar Syndrome Drug Sales in Value by Country (2024-2029)
6 Europe Crigler-Najjar Syndrome Drug by Country
6.1 Europe Crigler-Najjar Syndrome Drug Historic Market Size by Country
6.1.1 Europe Crigler-Najjar Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Crigler-Najjar Syndrome Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Crigler-Najjar Syndrome Drug Sales in Value by Country (2018-2023)
6.2 Europe Crigler-Najjar Syndrome Drug Forecasted Market Size by Country
6.2.1 Europe Crigler-Najjar Syndrome Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Crigler-Najjar Syndrome Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Crigler-Najjar Syndrome Drug by Region
7.1 Asia-Pacific Crigler-Najjar Syndrome Drug Historic Market Size by Region
7.1.1 Asia-Pacific Crigler-Najjar Syndrome Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Crigler-Najjar Syndrome Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Crigler-Najjar Syndrome Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Crigler-Najjar Syndrome Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Crigler-Najjar Syndrome Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Crigler-Najjar Syndrome Drug Sales in Value by Region (2024-2029)
8 Latin America Crigler-Najjar Syndrome Drug by Country
8.1 Latin America Crigler-Najjar Syndrome Drug Historic Market Size by Country
8.1.1 Latin America Crigler-Najjar Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Crigler-Najjar Syndrome Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Crigler-Najjar Syndrome Drug Sales in Value by Country (2018-2023)
8.2 Latin America Crigler-Najjar Syndrome Drug Forecasted Market Size by Country
8.2.1 Latin America Crigler-Najjar Syndrome Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Crigler-Najjar Syndrome Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Crigler-Najjar Syndrome Drug by Country
9.1 Middle East and Africa Crigler-Najjar Syndrome Drug Historic Market Size by Country
9.1.1 Middle East and Africa Crigler-Najjar Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Crigler-Najjar Syndrome Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Crigler-Najjar Syndrome Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Crigler-Najjar Syndrome Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Crigler-Najjar Syndrome Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Crigler-Najjar Syndrome Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Audentes Therapeutics Inc
10.1.1 Audentes Therapeutics Inc Company Information
10.1.2 Audentes Therapeutics Inc Introduction and Business Overview
10.1.3 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Products Offered
10.1.5 Audentes Therapeutics Inc Recent Development
10.2 Genethon SA
10.2.1 Genethon SA Company Information
10.2.2 Genethon SA Introduction and Business Overview
10.2.3 Genethon SA Crigler-Najjar Syndrome Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Genethon SA Crigler-Najjar Syndrome Drug Products Offered
10.2.5 Genethon SA Recent Development
10.3 International Stem Cell Corp
10.3.1 International Stem Cell Corp Company Information
10.3.2 International Stem Cell Corp Introduction and Business Overview
10.3.3 International Stem Cell Corp Crigler-Najjar Syndrome Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 International Stem Cell Corp Crigler-Najjar Syndrome Drug Products Offered
10.3.5 International Stem Cell Corp Recent Development
10.4 Promethera Biosciences SA
10.4.1 Promethera Biosciences SA Company Information
10.4.2 Promethera Biosciences SA Introduction and Business Overview
10.4.3 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Products Offered
10.4.5 Promethera Biosciences SA Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Crigler-Najjar Syndrome Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Crigler-Najjar Syndrome Drug Industrial Chain Analysis
11.4 Crigler-Najjar Syndrome Drug Market Dynamics
11.4.1 Crigler-Najjar Syndrome Drug Industry Trends
11.4.2 Crigler-Najjar Syndrome Drug Market Drivers
11.4.3 Crigler-Najjar Syndrome Drug Market Challenges
11.4.4 Crigler-Najjar Syndrome Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Crigler-Najjar Syndrome Drug Distributors
12.3 Crigler-Najjar Syndrome Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
